SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
12680167
Source:
http://linkedlifedata.com/resource/pubmed/id/12680167
Search
Subject
(
52
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0005290
,
umls-concept:C0026882
,
umls-concept:C0029925
,
umls-concept:C0086418
,
umls-concept:C0522498
pubmed:issue
1B
pubmed:dateCreated
2003-4-8
pubmed:abstractText
The interaction between paclitaxel and its target, beta tubulin, is essential for effective cytotoxicity. Alterations or mutation of beta tubulin have the potential to alter paclitaxel binding and confer a drug resistant phenotype.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/8102988
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin
,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin
,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm
,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel
,
http://linkedlifedata.com/resource/pubmed/chemical/Tubulin
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed-author:DuanZhenfengZ
,
pubmed-author:LamendolaDiana EDE
,
pubmed-author:OlivaEstherE
,
pubmed-author:PensonRichard TRT
,
pubmed-author:SeidenMichael VMV
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
681-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12680167-Adult
,
pubmed-meshheading:12680167-Aged
,
pubmed-meshheading:12680167-Antineoplastic Combined Chemotherapy Protocols
,
pubmed-meshheading:12680167-Carboplatin
,
pubmed-meshheading:12680167-Cisplatin
,
pubmed-meshheading:12680167-Combined Modality Therapy
,
pubmed-meshheading:12680167-DNA, Neoplasm
,
pubmed-meshheading:12680167-Exons
,
pubmed-meshheading:12680167-Female
,
pubmed-meshheading:12680167-Humans
,
pubmed-meshheading:12680167-Middle Aged
,
pubmed-meshheading:12680167-Ovarian Neoplasms
,
pubmed-meshheading:12680167-Paclitaxel
,
pubmed-meshheading:12680167-Point Mutation
,
pubmed-meshheading:12680167-Polymerase Chain Reaction
,
pubmed-meshheading:12680167-Polymorphism, Single-Stranded Conformational
,
pubmed-meshheading:12680167-Retrospective Studies
,
pubmed-meshheading:12680167-Tubulin
pubmed:articleTitle
beta tubulin mutations are rare in human ovarian carcinoma.
pubmed:affiliation
Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
pubmed:publicationType
Journal Article
,
Research Support, Non-U.S. Gov't